Second generation tyrosine kinase inhibitor therapy associated with significant carotid stenosis onset: A clinical case report and literature review.

Alberto Bramucci; Elisa Peretti; Maria Teresa Corsetti; Gabriele Colò; Alberto Guagliano

doi:10.23750/abm.v95i5.15459

Second generation tyrosine kinase inhibitor therapy associated with significant carotid stenosis onset: A clinical case report and literature review.

Authors

Alberto Bramucci Vascular Surgery, Cardio-Thoracic and Vascular Department, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy. https://orcid.org/0000-0003-4235-6593
Elisa Peretti Vascular Surgery, Cardio-Thoracic and Vascular Department, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Maria Teresa Corsetti Hematology Division, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Gabriele Colò Department of Orthopaedics and Traumatology, Regional Center for Joint Arthroplasty, ASO Alessandria, Alessandria, Italy.
Alberto Guagliano Vascular Surgery, Cardio-Thoracic and Vascular Department, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.

DOI: https://doi.org/10.23750/abm.v95i5.15459

Keywords:

tyrosine kinase inhibitors , carotid stenosis , chronic myeloid leukaemia

Abstract

Introduction: Tyrosine kinase inhibitors (TKI) are employed in the treatment of chronic myeloid leukemia (CML). Concerns about cardiovascular side effects have evolved, especially in patients with cardiovascular risk factors. Recommendations published in 2020 stress the need for preventative, biannual peripheral arterial evaluations, but there is no mention of carotid artery surveillance. We describe significant carotid artery stenosis onset in a young patient with CML treated with TKI therapy, without baseline cardiovascular risk factors. Case: A 55-year-old man was diagnosed with CML in 2016 and was prescribed Nilotinib 300 mg twice daily. Anamnesis reported identified a positive family history for cardiovascular disease only. Supra-aortic vessels Doppler ultrasound (DUS) in 2021 confirmed insignificant left internal carotid artery (ICA) stenosis, which increased to ICA stenosis with hemodynamic consequences, observed in 2023. A computed tomography angiography (CTA) confirmed stenotic progression, estimated between 80-85% over a 2-year period. A multidisciplinary team suggested revascularization with carotid endarterectomy (CEA) performed under general anesthesia with instrumental cerebral intraoperative monitoring. The patient had an uneventful post-procedural course and was discharged post-operative day 2. Post-operative 30-day DUS confirmed ongoing technical success.Conclusion: Our case report emphasizes the need for clinician awareness of a potential risk of carotid artery disease onset in patients undergoing Nilotinib therapy, independently of age and baseline cardiovascular risk factors.

References

Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22:14-22. doi: 10.1038/sj.leu.2404955.

Geary CG. The story of chronic myeloid leukaemia. Br J Haematol 2000; 110:2-11. doi: 10.1046/j.1365-2141.2000.02137.x.

Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000; 105:3–7. doi: 10.1172/JCI9083.

Aghel N, Lipton JH, Atenafu EG, Kim DDH, Delgado DH. Cardiovascular events after exposure to nilotinib in chronic meloid leukemia: long-term follow-up. Clin Lymphoma Myeloma Leuk 2017; 17: 870–878. doi: 10.1016/j.clml.2017.07.006.

Gugliotta G, Castagnetti F, Breccia M, et al. Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. Haematologica 2015; 100:1146–1150. doi: 10.3324/haematol.2015.129221.

Rix U, Hantschel O, Dürnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007; 110: 4055–4063. doi: 10.1182/blood-2007-07-102061.

Le Coutre P, Rea D, Abruzzese E, et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst 2011; 103:1347-1348. doi: 10.1093/jnci/djr292.

Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011; 86:533-539. doi: 10.1002/ajh.22037.

Ferguson GG, Eliasziw M, Barr HW, et al. The North American symptomatic carotid endarterectomy trial: surgical results in 1415 patients. Stroke 1999; 30:1751-8. doi: 10.1161/01.str.30.9.1751.

Yoshimura T, Matsuyama W, Kamohara H. Discoidin domain receptor 1: a new class of receptor regulating leukocyte-collagen interaction. Immunol Res 2005; 31:219–230. doi: 10.1385/IR:31:3:219.

Vasiliadis I, Kolovou G, Mikhailidis DP. Cardiotoxicity and Cancer Therapy. Angiology. 2014; 65:369-371. doi: 10.1177/0003319713498298.

Katgı A, Sevindik ÖG, Gökbulut AA, et al. Nilotinib Does Not Alter the Secretory Functions of Carotid Artery Endothelial Cells in a Prothrombotic or Antithrombotic Fashion. Clin Appl Thromb Hemost 2015; 21:678-683. doi: 10.1177/1076029614550817.

Alhawiti N, Burbury KL, Kwa FA, et al. The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state. Thromb Res 2016; 145:54–64. doi: 10.1016/j.thromres.2016.07.019.

Hersant J, Gardembas M, Leftheriotis G, Vandeputte P, Abraham P, Henni S. Tyrosine kinase inhibitor-induced carotid stenosis: A case report. Leuk Res Rep 2019 May 25; 12:1001-71. doi: 10.1016/j.lrr.2019.100171.

Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020; 34:966-984. doi: 10.1038/s41375-020-0776-2.

Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukemia. Leukemia 2016; 30:1648–1671. doi: 10.1038/leu.2016.104.